Lymphokine-Induced Macrophage Resistance to Infection with Leishmania Major

  • Miodrag Belosevic
  • Charles E. Davis
  • Monte S. Meltzer
  • Carol A. Nacy
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 239)


Leishmania are obligately intracellular protozoan parasites whose host cell within Infected humans and experimental animals Is the macrophage. Development of an effective Immune response to these organisms presents a unique immunologic predicament: the cell that sustains parasite viability within the host is also the central effector cell for induction of immune responses and expression of cytotoxic effector reactions. Once the parasite Is inside a macrophage, It Is protected from many of the humoral host defense mechanisms that develop during Infectious diseases. Resolution of infection, then, is primarily dependent upon extraordinary alterations In the intracellular environment of the macrophage that lead to death of the parasite, or elimination of the Infected cell itself (4,8,9). An alternative approach for intervention in the cycle of infection with Leishmania Is the development of macrophages resistant to Infection with the parasite. Macrophages from animals that are undergoing a vigorous Immune response to an infectious agent ingest fewer obligate or facultatively Intracellular pathogens in vitro than macrophages from uninfected mice (8,14). In fact, this decreased uptake of parasites, which we call “resistance to infection”, has been observed in activated macrophages obtained from mice Infected with Mycobacterium bovis strain BCG, as well as macrophages from L. donovanI-infected mice that were resolving systemic disease (5,14).


Bone Marrow Macrophage Walter Reed Army Institute Resident Peritoneal Macrophage Intracellular Protozoan Parasite Macrophage Activation Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Blanden, R.V., M.J. Lefford, and G.B. Mackaness. 1969. J. Exp. Med. 129: 1079.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Hoff, R. 1975. J. Exp. Med. 142: 299.PubMedCrossRefGoogle Scholar
  3. 3.
    Horwitz, M.A., and S.C. Silverstein. 1981. J. Exp. Med. 154: 1618.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Meltzer, M.S., and C.A. Nacy. 1980. Cell. Immunol. 54: 487.PubMedCrossRefGoogle Scholar
  5. 5.
    Millar, H.C., and D.W. Twohy. 1969. J. Parasitol. 55: 200.CrossRefGoogle Scholar
  6. 6.
    Nacy, C.A., and M.S. Meltzer. 1979. J. Immunol. 123: 2544.PubMedGoogle Scholar
  7. 7.
    Nacy, C.A., M.S. Meltzer, E.J. Leonard, and D.J. Wyler. 1981. J. Immunol. 127: 2381.PubMedGoogle Scholar
  8. 8.
    Nacy, C.A., and M.S. Meltzer. 1982. Infect. Immun. 36: 1096.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Nacy, C.A., A.H. Fortier, M.G. Pappas, and R.R. Henry. 1983. Cell. Immunol. 177: 298.CrossRefGoogle Scholar
  10. 10.
    Nacy, C.A., C.N. Oster, S.L. James, and M.S. Meltzer. 1984. Cont. Topics Immunobiol. 14: 147.Google Scholar
  11. 11.
    Nyka, W. 1956. Am. Rev. Tuberc. 73: 251.PubMedGoogle Scholar
  12. 12.
    Oster, C.N., and C.A. Nacy. 1984. J. Immunol. 132: 1494.PubMedGoogle Scholar
  13. 13.
    Panosian, C.B., and D.J. Wyler. 1983. J. Infect. Dis. 148: 1049.PubMedCrossRefGoogle Scholar
  14. 14.
    Pappas, M.G., and C.A. Nacy. 1983. Cell. Immunol. 80: 222.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Miodrag Belosevic
    • 1
  • Charles E. Davis
    • 1
  • Monte S. Meltzer
    • 1
  • Carol A. Nacy
    • 1
  1. 1.Department of ImmunologyWalter Reed Army Institute of ResearchUSA

Personalised recommendations